- Home
- MESO vs SGML Comparison
MESO vs SGML Comparison
Compare MESO & SGML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- SGML
- Stock Information
- Founded
- MESO 2004
- SGML 2011
- Country
- MESO Australia
- SGML Brazil
- Employees
- MESO N/A
- SGML N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- SGML Industrial Machinery/Components
- Sector
- MESO Health Care
- SGML Industrials
- Exchange
- MESO Nasdaq
- SGML Nasdaq
- Market Cap
- MESO 1.1B
- SGML 1.2B
- IPO Year
- MESO N/A
- SGML N/A
- Fundamental
- Price
- MESO $9.44
- SGML $14.40
- Analyst Decision
- MESO Strong Buy
- SGML Strong Buy
- Analyst Count
- MESO 4
- SGML 2
- Target Price
- MESO $11.50
- SGML $24.50
- AVG Volume (30 Days)
- MESO 208.8K
- SGML 843.9K
- Earning Date
- MESO 08-28-2024
- SGML 11-12-2024
- Dividend Yield
- MESO N/A
- SGML N/A
- EPS Growth
- MESO N/A
- SGML N/A
- EPS
- MESO N/A
- SGML 0.08
- Revenue
- MESO $5,902,000.00
- SGML $215,173,346.00
- Revenue This Year
- MESO $66.05
- SGML $49.45
- Revenue Next Year
- MESO $348.27
- SGML $93.93
- P/E Ratio
- MESO N/A
- SGML $184.64
- Revenue Growth
- MESO N/A
- SGML N/A
- 52 Week Low
- MESO $1.61
- SGML $8.47
- 52 Week High
- MESO $11.05
- SGML $34.31
- Technical
- Relative Strength Index (RSI)
- MESO 57.58
- SGML 56.73
- Support Level
- MESO $9.55
- SGML $13.19
- Resistance Level
- MESO $10.30
- SGML $14.26
- Average True Range (ATR)
- MESO 0.58
- SGML 0.69
- MACD
- MESO -0.07
- SGML -0.07
- Stochastic Oscillator
- MESO 21.22
- SGML 38.32
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About SGML Sigma Lithium Corporation
Sigma Lithium Corp is dedicated to powering the next generation of electric vehicle batteries with environmentally sustainable and high-purity lithium. The company is in construction at its wholly owned Grota do Cirilo Project in Brazil, one of the highest-grade hard rock lithium spodumene deposits in the Americas.